The Filings Report

Jazz Pharmaceuticals, Inc.

JAZZNasdaqCIK 1232524Healthcare / Drug Manufacturersfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$1.2B
+10.4% on Q3 FY2025
Net income
−$483M
−292.3% on Q3 FY2025
Free cash flow
$490M
+6.6% on Q3 FY2025
Diluted EPS
$-7.48
−283.3% on Q3 FY2025
Revenue, TTM
$4.7B
trailing four quarters
Net margin, TTM
4.4%
net income $206M
Free cash flow, TTM
$1.6B
$1.7B less $71M capex
Cash and equivalents
$2.0B
long-term debt $4.6B, Sep 30, 2026
Shares, 12-month change
+5.6%
64M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$13.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 2, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Jazz Pharmaceuticals, Inc. reported revenue of $1.2B, +10.4% on Q3 FY2025, and net loss of $483M (−292.3%). Operating margin was −33.3%. Free cash flow, operating cash flow less capital expenditures, was $490M ($506M less $16M). Diluted earnings per share were $-7.48.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 2, 2026.

Revenue and net incomeRevenueNet income
−$1.0B−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $972MQ4'22, Net income: −$241MQ4'22Q1'23, Revenue: $893MQ1'23, Net income: $69MQ1'23Q2'23, Revenue: $957MQ2'23, Net income: $104MQ2'23Q3'23, Revenue: $972MQ3'23, Net income: $147MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $94MQ4'23Q1'24, Revenue: $902MQ1'24, Net income: −$15MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: $169MQ2'24Q3'24, Revenue: $1.1BQ3'24, Net income: $215MQ3'24Q4'24, Revenue: $1.1BQ4'24, Net income: $191MQ4'24Q1'25, Revenue: $898MQ1'25, Net income: −$93MQ1'25Q2'25, Revenue: $1.0BQ2'25, Net income: −$719MQ2'25Q3'25, Revenue: $1.1BQ3'25, Net income: $251MQ3'25Q4'25, Revenue: $1.2BQ4'25, Net income: $203MQ4'25Q1'26, Revenue: $1.1BQ1'26, Net income: $293MQ1'26Q2'26, Revenue: $1.2BQ2'26, Net income: $193MQ2'26Q3'26, Revenue: $1.2BQ3'26, Net income: −$483MQ3'26−$1.0B−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $972MQ4'22, Net income: −$241MQ1'23, Revenue: $893MQ1'23, Net income: $69MQ1'23Q2'23, Revenue: $957MQ2'23, Net income: $104MQ3'23, Revenue: $972MQ3'23, Net income: $147MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $94MQ1'24, Revenue: $902MQ1'24, Net income: −$15MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: $169MQ3'24, Revenue: $1.1BQ3'24, Net income: $215MQ3'24Q4'24, Revenue: $1.1BQ4'24, Net income: $191MQ1'25, Revenue: $898MQ1'25, Net income: −$93MQ1'25Q2'25, Revenue: $1.0BQ2'25, Net income: −$719MQ3'25, Revenue: $1.1BQ3'25, Net income: $251MQ3'25Q4'25, Revenue: $1.2BQ4'25, Net income: $203MQ1'26, Revenue: $1.1BQ1'26, Net income: $293MQ1'26Q2'26, Revenue: $1.2BQ2'26, Net income: $193MQ3'26, Revenue: $1.2BQ3'26, Net income: −$483MQ3'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600MQ4'22, Free cash flow: $333MQ4'22Q1'23, Free cash flow: $317MQ1'23Q2'23, Free cash flow: $291MQ2'23Q3'23, Free cash flow: $303MQ3'23Q4'23, Free cash flow: $157MQ4'23Q1'24, Free cash flow: $260MQ1'24Q2'24, Free cash flow: $324MQ2'24Q3'24, Free cash flow: $388MQ3'24Q4'24, Free cash flow: $385MQ4'24Q1'25, Free cash flow: $416MQ1'25Q2'25, Free cash flow: $76MQ2'25Q3'25, Free cash flow: $460MQ3'25Q4'25, Free cash flow: $346MQ4'25Q1'26, Free cash flow: $389MQ1'26Q2'26, Free cash flow: $398MQ2'26Q3'26, Free cash flow: $490MQ3'26$0$200M$400M$600MQ4'22, Free cash flow: $333MQ1'23, Free cash flow: $317MQ1'23Q2'23, Free cash flow: $291MQ3'23, Free cash flow: $303MQ3'23Q4'23, Free cash flow: $157MQ1'24, Free cash flow: $260MQ1'24Q2'24, Free cash flow: $324MQ3'24, Free cash flow: $388MQ3'24Q4'24, Free cash flow: $385MQ1'25, Free cash flow: $416MQ1'25Q2'25, Free cash flow: $76MQ3'25, Free cash flow: $460MQ3'25Q4'25, Free cash flow: $346MQ1'26, Free cash flow: $389MQ1'26Q2'26, Free cash flow: $398MQ3'26, Free cash flow: $490MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6B$8BQ4'22, Cash and equivalents: $881MQ4'22, Long-term debt: $5.7BQ4'22Q1'23, Cash and equivalents: $1.2BQ1'23, Long-term debt: $5.7BQ1'23Q2'23, Cash and equivalents: $1.3BQ2'23, Long-term debt: $5.7BQ2'23Q3'23, Cash and equivalents: $1.3BQ3'23, Long-term debt: $5.1BQ3'23Q4'23, Cash and equivalents: $1.5BQ4'23, Long-term debt: $5.1BQ4'23Q1'24, Cash and equivalents: $1.4BQ1'24, Long-term debt: $5.1BQ1'24Q2'24, Cash and equivalents: $1.4BQ2'24, Long-term debt: $5.1BQ2'24Q3'24, Cash and equivalents: $2.2BQ3'24, Long-term debt: $6.1BQ3'24Q4'24, Cash and equivalents: $2.4BQ4'24, Long-term debt: $6.1BQ4'24Q1'25, Cash and equivalents: $1.9BQ1'25, Long-term debt: $5.3BQ1'25Q2'25, Cash and equivalents: $1.2BQ2'25, Long-term debt: $4.3BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $4.3BQ3'25Q4'25, Cash and equivalents: $1.4BQ4'25, Long-term debt: $4.3BQ4'25Q1'26, Cash and equivalents: $1.8BQ1'26, Long-term debt: $4.3BQ1'26Q2'26, Cash and equivalents: $1.6BQ2'26, Long-term debt: $3.3BQ2'26Q3'26, Cash and equivalents: $2.0BQ3'26, Long-term debt: $4.6BQ3'26$0$2B$4B$6B$8BQ4'22, Cash and equivalents: $881MQ4'22, Long-term debt: $5.7BQ1'23, Cash and equivalents: $1.2BQ1'23, Long-term debt: $5.7BQ1'23Q2'23, Cash and equivalents: $1.3BQ2'23, Long-term debt: $5.7BQ3'23, Cash and equivalents: $1.3BQ3'23, Long-term debt: $5.1BQ3'23Q4'23, Cash and equivalents: $1.5BQ4'23, Long-term debt: $5.1BQ1'24, Cash and equivalents: $1.4BQ1'24, Long-term debt: $5.1BQ1'24Q2'24, Cash and equivalents: $1.4BQ2'24, Long-term debt: $5.1BQ3'24, Cash and equivalents: $2.2BQ3'24, Long-term debt: $6.1BQ3'24Q4'24, Cash and equivalents: $2.4BQ4'24, Long-term debt: $6.1BQ1'25, Cash and equivalents: $1.9BQ1'25, Long-term debt: $5.3BQ1'25Q2'25, Cash and equivalents: $1.2BQ2'25, Long-term debt: $4.3BQ3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $4.3BQ3'25Q4'25, Cash and equivalents: $1.4BQ4'25, Long-term debt: $4.3BQ1'26, Cash and equivalents: $1.8BQ1'26, Long-term debt: $4.3BQ1'26Q2'26, Cash and equivalents: $1.6BQ2'26, Long-term debt: $3.3BQ3'26, Cash and equivalents: $2.0BQ3'26, Long-term debt: $4.6BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Jazz Pharmaceuticals, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,2431,2081,0691,1981,1261,0468981,088+10.4%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative408389353406531358514369−23.1%
Operating income(413)24833725558(686)(56)191−819.0%
Other income (expense)—————————
Pretax income(459)2112992099(736)(110)133−5198.9%
Income tax251865(242)(17)(18)(58)+110.1%
Net income(483)193293203251(718)(92)191−292.3%
Diluted EPS ($)(7.48)2.784.43—4.08(11.74)(1.52)—−283.3%
Diluted shares (millions)656966—626161——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Jazz Pharmaceuticals, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents2,0361,6201,8441,3921,3261,1901,8622,413+53.6%
Short-term investments—————————
Total current assets4,6133,9684,5834,1663,7563,3504,1284,629+22.8%
Total assets11,99811,08111,86011,65911,35610,94411,53512,012+5.6%
Total current liabilities2,5332,2312,2472,2432,2742,0711,2231,039+11.4%
Long-term debt4,5523,3354,3244,3284,3324,3365,3366,078+5.1%
Total liabilities—————————
Stockholders’ equity4,1924,8024,5324,3193,9593,7064,1754,094+5.9%
Shares outstanding (millions)6465636261616261—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Jazz Pharmaceuticals, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow50641640836247589430399+6.6%
Capital expenditures1618201715131413+6.6%
Free cash flow (CFO − capex)49039838934646076416385+6.6%
Depreciation and amortization—————————
Share repurchases225——00——0—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Jazz Pharmaceuticals, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Revenue4,2684,0693,8343,6593,0942,3642,1621,8911,6191,4881,3251,173872586272174128
Cost of revenue—————————————————
Gross profit—————————————————
Research and development——————300227198162135854220142637
Selling, general and administrative1,8091,3851,3431,4171,4528547376845445034494063042241096959
Operating income(430)717579(66)1703785326155295925081963401981285816
Other income (expense)——————————19(2)————
Pretax income(628)470298(373)(113)27545452944153243615230817712533—
Income tax(272)(91)(120)(159)21634(73)80(48)1351069492(84)00—
Net income(356)560415(224)(330)2395234474883973305821628912533(7)
Diluted EPS ($)(5.84)8.656.10(3.58)(5.52)4.229.097.307.966.415.230.933.514.792.670.83(0.23)
Diluted shares (millions)6166726360575861616263636260473930

Balance sheet

Jazz Pharmaceuticals, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Cash and equivalents1,3922,4131,5068815911,058637310386366989684637387824516
Short-term investments—————————————————
Total current assets4,1664,6293,4352,6062,6112,8401,6301,2349687481,2581,01686555219974—
Total assets11,65912,01211,39310,83512,2996,5365,5395,2035,1244,8003,3333,3392,2381,966254136—
Total current liabilities2,2431,0391,5379338096543643452942572272172041925360—
Long-term debt4,3286,0785,1085,6936,0191,8491,5741,5631,5401,9941,1511,3335444270——
Total liabilities—————————————————
Stockholders’ equity4,3194,0943,7373,0863,9653,6603,1112,7572,7131,8771,7061,3711,2961,12119331(73)
Shares outstanding (millions)626162636256565760606161585856——

Cash flow statement

Jazz Pharmaceuticals, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Operating cash flow1,3561,3961,0921,27277990077679969359253240828825015259(16)
Capital expenditures593824292815402029103636106110
Free cash flow (CFO − capex)1,2971,3581,0681,24375188573677966458349637127824415058(16)
Depreciation and amortization4233303027191515131210——————
Share repurchases1253112700014730152499278624213600——
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$23M
11 sales by 4 insiders; officers and directors $23M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$70M
59 sales by 11 insiders; officers and directors $70M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 6, 2026Gala Renee DPresident & CEO, Directoropen-market sale10b5-12,000$236.40$473K141,394Oct 7, 2026
Oct 1, 2026Cozadd Bruce CDirectoropen-market sale10b5-16,000$230.33$1M345,875Oct 5, 2026
Sep 10, 2026Patil Neena MEVP & Chief Legal Officeropen-market sale10b5-11,200$240.94$289K47,671Sep 14, 2026
Sep 8, 2026Gala Renee DPresident & CEOtax withholding1,967$246.81$485K145,394Sep 10, 2026
Sep 8, 2026Gala Renee DPresident & CEOopen-market sale10b5-12,000$243.03$486K143,394Sep 10, 2026
Sep 8, 2026Henderson Mary ElizabethSVP, Technical Operationstax withholding1,412$243.03$343K23,830Sep 10, 2026
Sep 8, 2026Henderson Mary ElizabethSVP, Technical Operationstax withholding15$241.20$4K23,815Sep 10, 2026
Sep 1, 2026Cozadd Bruce CDirectoropen-market sale10b5-16,000$250.13$2M351,875Sep 2, 2026
Aug 31, 2026Henderson Mary ElizabethSVP, Technical Operationstax withholding2,076$241.39$501K25,258Sep 2, 2026
Aug 31, 2026Henderson Mary ElizabethSVP, Technical Operationstax withholding16$244.64$4K25,242Sep 2, 2026
Aug 31, 2026Smith Mark DouglasDirectortax withholding14$244.64$3K11,271Sep 2, 2026
Aug 31, 2026Smith Mark DouglasDirectortax withholding1,692$241.39$408K9,579Sep 2, 2026
Aug 31, 2026Riedel Norbert GDirectortax withholding14$244.64$3K8,615Sep 2, 2026
Aug 31, 2026Riedel Norbert GDirectortax withholding1,692$241.39$408K6,923Sep 2, 2026
Aug 31, 2026Love Ted WDirectortax withholding6$244.06$1K3,126Sep 2, 2026
Aug 31, 2026Love Ted WDirectortax withholding737$241.39$178K2,389Sep 2, 2026
Aug 31, 2026Hamill LauraDirectortax withholding14$244.06$3K8,524Sep 2, 2026
Aug 31, 2026Hamill LauraDirectortax withholding1,692$241.39$408K6,832Sep 2, 2026
Aug 31, 2026Cook Jennifer E.Directortax withholding14$244.06$3K12,428Sep 2, 2026
Aug 31, 2026Cook Jennifer E.Directortax withholding1,692$241.39$408K10,736Sep 2, 2026
Aug 31, 2026Enright Patrick GDirectortax withholding14$244.64$3K22,970Sep 2, 2026
Aug 31, 2026Enright Patrick GDirectortax withholding1,692$241.39$408K21,278Sep 2, 2026
Aug 31, 2026McSharry Heather AnnDirectortax withholding15$244.64$4K20,039Sep 2, 2026
Aug 31, 2026McSharry Heather AnnDirectortax withholding1,840$241.39$444K18,199Sep 2, 2026
Aug 31, 2026Kennedy PatrickDirectortax withholding15$244.06$4K8,292Sep 2, 2026

Full insider history for Jazz Pharmaceuticals, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Jazz Pharmaceuticals plc, CIK 1232524 on EDGAR
Extract generated
November 4, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: revenue FY2010
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2010
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: not filed
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/JAZZ.json